213 related articles for article (PubMed ID: 7125859)
41. Cancer of the breast. Endocrine ablation, hormone therapy and chemotherapy.
Donegan WL
Major Probl Clin Surg; 1967; 5():201-44. PubMed ID: 5005673
[No Abstract] [Full Text] [Related]
42. The prediction of hormonal dependency of mammary cancer.
Block GE; Jensen EV; Polley TZ
Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754
[TBL] [Abstract][Full Text] [Related]
43. [Hormone treatment of metastasizing breast carcinoma].
Navarra S; Melita P; Di Mauro S; Calbo L; Belnome N
Minerva Chir; 1981 Jun; 36(12):853-60. PubMed ID: 6454856
[TBL] [Abstract][Full Text] [Related]
44. Estrogen receptors and breast cancer response to adrenalectomy.
Jensen EV; Block GE; Smith S; Kyser K; DeSombre ER
Natl Cancer Inst Monogr; 1971 Dec; 34():55-70. PubMed ID: 5140877
[No Abstract] [Full Text] [Related]
45. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
46. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
47. [Therapeutic problems in hormone-dependent cancer].
Zimel H
Stud Cercet Endocrinol; 1969; 20(2):111-25. PubMed ID: 4898947
[No Abstract] [Full Text] [Related]
48. [Metastatic breast cancers: comparison of the prognostic significance and the sensitivity to chemotherapy according to the presence of estradiol and progesterone receptors].
Pouillart P; Madgelenat H; Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Polijcak M; Asselain B
Bull Cancer; 1982; 69(5):461-7. PubMed ID: 7165808
[TBL] [Abstract][Full Text] [Related]
49. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
50. [Hormone therapy of breast cancer].
Zhivetskiĭ AV; Kleĭman SM; Petruk VI; Zhivetskiĭ VA
Vrach Delo; 1975 Sep; (9):99-101. PubMed ID: 1210314
[No Abstract] [Full Text] [Related]
51. [Analysis of hormone receptors in the treatment of breast neoplasms in women].
Delarue JC; Bohuon C
Ann Biol Clin (Paris); 1980; 38(5):293-6. PubMed ID: 7469145
[TBL] [Abstract][Full Text] [Related]
52. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
53. Endocrine manipulation in the treatment of breast cancer.
Segaloff A
Clin Obstet Gynecol; 1975 Jun; 18(2):227-37. PubMed ID: 166781
[No Abstract] [Full Text] [Related]
54. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
55. [Endocrine therapy of the metastatic breast cancer. I. Ablative hormonal therapy (ovariectomy, adrenalectomy, hypophysectomy)].
Gacci G; Torre GC; Pedotti G; Gannizzo G
Acta Obstet Ginecol Hisp Lusit; 1977 Dec; 25(9):519-28. PubMed ID: 612117
[No Abstract] [Full Text] [Related]
56. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
57. Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53.
Rahko E; Blanco G; Bloigu R; Soini Y; Talvensaari-Mattila A; Jukkola A
Breast; 2006 Feb; 15(1):69-75. PubMed ID: 16005229
[TBL] [Abstract][Full Text] [Related]
58. Clinical response to hormone therapy correlated with estrogen receptor analyses. Biochemical v histochemical methods.
McCarty KS; Hiatt KB; Budwit DA; Cox EB; Leight G; Reintgen D; Georgiade G; McCarty KS; Siegler HF
Arch Pathol Lab Med; 1984 Jan; 108(1):24-6. PubMed ID: 6546332
[TBL] [Abstract][Full Text] [Related]
59. [Selective mechanisms of hormonal therapy].
Stoll BA
Vopr Onkol; 1979; 25(5):67-75. PubMed ID: 380153
[TBL] [Abstract][Full Text] [Related]
60. Hormonal therapy of breast cancer.
Segaloff A
Cancer Treat Rev; 1975 Jun; 2(2):129-35. PubMed ID: 1102087
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
